Piperidines Patents (Class 514/315)
  • Patent number: 11903938
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: March 26, 2021
    Date of Patent: February 20, 2024
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Patent number: 11826360
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: November 28, 2023
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Patent number: 11820749
    Abstract: In alternative embodiments, provided are uncharged bis-oxime antidotes that cross the blood-brain barrier (BBB) to catalyze the hydrolysis of organophosphate (OP)-inhibited human acetylcholinesterase (hAChE) in the central nerve system (CNS). In alternative embodiments, provided are pumps, devices, subcutaneous infusion devices, continuous subcutaneous infusion devices, infusion pens, needles, reservoirs, ampoules, a vial, a syringe, a cartridge, a disposable pen or jet injector, a prefilled pen or a syringe or a cartridge, a cartridge or a disposable pen or jet injector, a two chambered or multi-chambered pump, a syringe, a cartridge or a pen or a jet injector, comprising a compound as provided herein.
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: November 21, 2023
    Assignees: The Regents of the University of California, Oak Ridge National Laboratory
    Inventors: Zoran Radic, Carlo Ballatore, Lukas Gorecki, Palmer Taylor, Andrey Kovalevsky, Xiaolin Cheng
  • Patent number: 11744833
    Abstract: Pharmaceutical compositions comprising azelastine or a pharmaceutically acceptable salt of azelastine and melatonin are disclosed. Methods of using the pharmaceutical compositions for treating patients suffering from insomnia are also disclosed.
    Type: Grant
    Filed: February 16, 2022
    Date of Patent: September 5, 2023
    Assignee: LA PharmaTech Inc.
    Inventors: Jianmin Wang, Fengyuan Jia
  • Patent number: 11713297
    Abstract: The invention relates to a crystalline form of [(2R,3S,4R,5S)-1-butyl-2-(hydroxymethyl)-piperidine-3,4,5-triol, processes for the preparation thereof, pharmaceutical compositions containing such a crystalline form, and its use as a medicament, especially as glycolipid biosynthesis inhibitor.
    Type: Grant
    Filed: September 20, 2021
    Date of Patent: August 1, 2023
    Assignee: Idorsia Pharmaceuticals Ltd
    Inventors: Vitor Oliveira, Ivan Pogorelic, Jean-Paul Roduit
  • Patent number: 11710547
    Abstract: The present disclosure relates to methods and systems suitable for use in identifying and providing personalised medicine to a patient. In some aspects, systems and method generate a co-therapy regimen for a patient suffering from a disease or condition. An identification of a co-therapy suitable to treat the disease or condition is received. A desired patient endpoint and a patient position are received, wherein the patient position is defined relative to the desired patient endpoint. A dataset relating to the patient is stored. The dataset comprises one or more patient data based on patient-related measurements. The dataset, the patient position and the desired patient endpoint are processed to generate a regimen for the co-therapy. The regimen is stored in a database.
    Type: Grant
    Filed: April 28, 2020
    Date of Patent: July 25, 2023
    Assignee: CLOSED LOOP MEDICINE LTD.
    Inventors: Paul Goldsmith, Hakim Adam Yadi, Andrew John McGlashan Richards, Felicity Kate Sartain, David Cox, David O'Regan
  • Patent number: 11642334
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: May 9, 2023
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Patent number: 11633388
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: April 25, 2023
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Patent number: 11633387
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: October 21, 2020
    Date of Patent: April 25, 2023
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Patent number: 11622962
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: April 11, 2023
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Patent number: 11612594
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: March 28, 2023
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Patent number: 11547704
    Abstract: The invention is directed to substituted piperidine derivatives. Specifically, the invention is directed to compounds according to Formula IIII: wherein A, B, X, Y, L1, L2, L3, R1, R2, R3, R4, R5, R6, R9, z2, z4, z5, and z6 are as defined herein, and salts thereof.
    Type: Grant
    Filed: June 11, 2020
    Date of Patent: January 10, 2023
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Jeffrey Michael Axten, Mui Cheung, Michael P. Demartino, Hilary Schenck Eidam, Raghava Reddy Kethiri, Biswajit Kalita
  • Patent number: 11505537
    Abstract: The present technology is directed to compositions comprising d-threo-methylphenidate conjugates and/or unconjugated methylphenidate. The present technology also relates to compositions and oral formulations comprising d-threo-methylphenidate conjugated to nicotinoyl-L-serine, and/or a pharmaceutically acceptable salt thereof, and unconjugated methylphenidate and/or a pharmaceutically acceptable salt thereof. The present technology additionally relates to a pharmaceutical kit containing the composition comprising d-threo-methylphenidate conjugated to nicotinoyl-L-serine, and/or a pharmaceutically acceptable salt thereof, and unconjugated methylphenidate and/or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 8, 2020
    Date of Patent: November 22, 2022
    Assignee: KEMPHARM, INC.
    Inventors: Travis Mickle, Sven Guenther, Guochen Chi
  • Patent number: 11390762
    Abstract: A tri-carboxylic compound of Formula (IA) optionally in combination with a compound of Formula (IIA) behaves as a low-VOC, low odor coalescing agent, while a tri-carboxylic compound of Formula (IA) in combination with a compound of Formula (IIB), or alternatively, a tri-carboxylic compound of Formula (IB) in combination with a compound of Formula (IIA) exhibits dual coalescing and plasticizing properties. A tri-carboxylic compound of Formula (IB) optionally in combination with a compound of Formula (IIB) behaves as low-VOC, low odor plasticizing agent.
    Type: Grant
    Filed: March 28, 2017
    Date of Patent: July 19, 2022
    Assignee: Ascend Performance Materials Operation LLC
    Inventors: Prasad Taranekar, Jeffery W. Balko
  • Patent number: 11357762
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: August 12, 2021
    Date of Patent: June 14, 2022
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Patent number: 11358926
    Abstract: The present invention provides novel compounds as well as compositions and methods using the same for preventing and/or treating degenerative disorders of the central nervous system and/or lysosomal storage disorders. In particular, the present invention provides methods for preventing and/or treating Parkinson's disease, Alzheimer's disease and/or Gaucher's disease.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: June 14, 2022
    Assignee: Amicus Therapeutics, Inc.
    Inventor: Robert Boyd
  • Patent number: 11357763
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: August 12, 2021
    Date of Patent: June 14, 2022
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Patent number: 11357761
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: August 12, 2021
    Date of Patent: June 14, 2022
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Patent number: 11292766
    Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: April 5, 2022
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Tatsuhiko Fujimoto, Kentaro Rikimaru, Koichiro Fukuda, Hiromichi Sugimoto, Takahiro Matsumoto, Norihito Tokunaga, Mariko Hirozane
  • Patent number: 11278538
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: August 12, 2021
    Date of Patent: March 22, 2022
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Patent number: 11278536
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: August 12, 2021
    Date of Patent: March 22, 2022
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Patent number: 11278537
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: August 12, 2021
    Date of Patent: March 22, 2022
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Patent number: 11278539
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: August 12, 2021
    Date of Patent: March 22, 2022
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Patent number: 11278540
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: March 22, 2022
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Patent number: 11241422
    Abstract: Provided are in vitro and in vivo methods for determining whether a patient with Fabry disease will respond to treatment with a specific pharmacological chaperone.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: February 8, 2022
    Assignee: Amicus Therapeutics, Inc.
    Inventors: David J. Lockhart, Jeff Castelli
  • Patent number: 10980789
    Abstract: A therapeutic agent for fibrosis, whose active ingredient is constituted by a glucosylceramide synthase inhibitor or lactosylceramide synthase inhibitor, or both, inhibits the nuclear translocation of phosphorylated Smad, thereby treating and preventing fibrosis.
    Type: Grant
    Filed: October 23, 2019
    Date of Patent: April 20, 2021
    Assignee: NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY
    Inventors: Hiroyuki Nakamura, Toshihiko Murayama
  • Patent number: 10898737
    Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: January 26, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko Fujimoto, Kentaro Rikimaru, Hiromichi Sugimoto, Takahiro Matsumoto
  • Patent number: 10874655
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: December 29, 2020
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Patent number: 10874656
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: December 29, 2020
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Patent number: 10874657
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: December 29, 2020
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Patent number: 10857142
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: December 8, 2020
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Patent number: 10857141
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: December 8, 2020
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Patent number: 10849889
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: December 1, 2020
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Patent number: 10849890
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: December 1, 2020
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Patent number: 10828291
    Abstract: Some embodiments disclosed herein include a method for decreasing gene expression of a gene. The methods can include identifying a human subject over the age of 35 and having an increase expression level of a gene associated with proteasome activity; and administering to the human subject an effective amount of a nitroxide antioxidant, whereby expression level of the gene is decreased.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: November 10, 2020
    Inventor: Louis Habash
  • Patent number: 10806727
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: October 20, 2020
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Patent number: 10799491
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: October 13, 2020
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Patent number: 10792278
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: October 6, 2020
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Patent number: 10792279
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: October 6, 2020
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Patent number: 10508083
    Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: December 17, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko Fujimoto, Kentaro Rikimaru, Koichiro Fukuda, Hiromichi Sugimoto, Takahiro Matsumoto
  • Patent number: 10500301
    Abstract: The present invention relates to the use, as an agent for salting out an active substance in a composition for a dressing, of a copolymer of a salt of 2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulphonic acid and the 2-hydroxyethyl ester of propenoic acid. It also relates to dressings of the type comprising at least one fatty substance and/or an elastomeric matrix and at least one active substance, which incorporate the aforementioned copolymer.
    Type: Grant
    Filed: May 23, 2008
    Date of Patent: December 10, 2019
    Assignee: URGO RECHERCHE INNOVATION ET DEVELOPPEMENT
    Inventor: Christelle Laurensou
  • Patent number: 10478427
    Abstract: A therapeutic agent for fibrosis, whose active ingredient is constituted by a glucosylceramide synthase inhibitor or lactosylceramide synthase inhibitor, or both, inhibits the nuclear translocation of phosphorylated Smad, thereby treating and preventing fibrosis.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: November 19, 2019
    Assignee: NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY
    Inventors: Hiroyuki Nakamura, Toshihiko Murayama
  • Patent number: 10406143
    Abstract: Provided are in vitro and in vivo methods for determining whether a patient with Fabry disease will respond to treatment with a specific pharmacological chaperone.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: September 10, 2019
    Assignee: Amicus Therapeutics, Inc.
    Inventors: David J. Lockhart, Jeff Castelli
  • Patent number: 10278942
    Abstract: The present disclosure provides methods of treating pulmonary arterial hypertension (PAH) in a subject in need thereof. Compositions for use in these methods are also provided.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: May 7, 2019
    Assignee: Peloton Therapeutics, Inc.
    Inventors: John A. Josey, Eli M. Wallace, Xinlin Du, Barry Goggin
  • Patent number: 10280140
    Abstract: The present invention relates to a method for the production of a pyrrolidine derivative.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: May 7, 2019
    Assignee: Eberhard Karls Universitaet Tuebingen Medizinische Fakultaet
    Inventors: Bernhard Hirt, Claus Zeyher
  • Patent number: 10245256
    Abstract: Pharmaceutical compositions are provided that are useful in treating diabetes. The compositions comprise a pharmaceutically acceptable carrier, and an effective therapeutic or prophylactic amount of a nitroxide antioxidant that alters the expression of genes related to diabetes. Methods are also provided for the use of the pharmaceutical compositions in the treatment or prevention of diabetes. In a preferred embodiment, the nitroxide antioxidant is Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl).
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: April 2, 2019
    Assignee: Mitos Pharmaceuticals, Inc.
    Inventors: Louis Habash, Clarence Jones
  • Patent number: 10179128
    Abstract: Described herein are dosing regimens and kits for the treatment and/or prevention of lysosomal storage disorders such as Gaucher disease. Also described are dosing regimens and kits for the treatment and/or prevention of degenerative disorders of the central nervous system, such as the synucleinopathies Parkinson's disease or Lewy Body Dementia.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: January 15, 2019
    Assignee: Amicus Therapeutics, Inc.
    Inventor: Sean Clark
  • Patent number: 10159665
    Abstract: Disclosed herein are embodiments of a method of inhibiting amyloid plaque deposition. In some embodiments, the method comprises: administering to an individual known to have a decreased expression level of Bri3 an amount of a nitroxide antioxidant effective to increase the BRI3 expression level relative to the decreased expression level, whereby the increased expression level of Bri3 inhibits amyloid plaque deposition via inhibition of amyloid precursor protein processing.
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: December 25, 2018
    Inventor: Louis Habash
  • Patent number: 10144727
    Abstract: The present application provide novel iminosugars and their use in treatment of viral infections, such as Dengue infection and Influenza A infection. The present inventors discovered certain deoxynojirimycin derivatives may be effective against one or more viruses, which may be, for example, a Dengue virus and/or a virus belonging to the Orthomyxoviridae family, such as an Influenza A virus. In particular, such deoxynojirimycin derivatives may be useful for treating a disease or condition caused by or associated with one or more viruses. In certain embodiments, the deoxynojirimycin derivatives may increase a survival rate or probability for a subject infected with one or more viruses, which may be, for example, a Dengue virus and/or a virus belonging to the Orthomyxoviridae family, such as an Influenza A virus.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: December 4, 2018
    Assignee: Emergent Virology LLC
    Inventors: Urban Ramstedt, Raju Penmasta, Hitesh Batra, Tam Nguyen
  • Patent number: 10077458
    Abstract: A process for the microbial synthesis of migalastat, specifically a process for the production of migalastat comprising culturing a microorganism under conditions such that at least one imino sugar is produced and detecting and/or isolating an imino sugar produced by said microorganism, and the microorganisms used in this process. The invention also comprises migalastat produced according to the above method and pharmaceutical compositions and uses thereof.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: September 18, 2018
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Emilio Alvarez-Ruiz, Andrew John Collis, Alison Sarah Dann, Andrew Peter Fosberry, Sarah Jane Ready, Maria Jesus Vazquez Muniz